Cardiovascular disease in patients with schizophrenia

Kritharides, Leonard; Chow, Vincent; Lambert, Tim JR

doi:10.5694/mja16.00650

ARTICLE
AUTHORS
REFERENCES

Topics

Cardiovascular diseases

Endocrine system diseases

Mental disorders

Pharmaceutical preparations

Summary

Patients with schizophrenia die on average 25 years earlier than the general population, and this gap appears to be increasing.
Most of the excess mortality is due to premature cardiovascular deaths rather than suicide.
Many psychotropic agents are orexigenic and can increase weight and promote dyslipidaemia.
Traditional cardiac risk factors are undertreated among patients with schizophrenia, and they are less likely to receive cardiac revascularisation than those without a mental illness.
Clozapine is an atypical antipsychotic medication effective for treatment of refractory schizophrenia, but is associated with the risk of myocarditis and cardiomyopathy.
Established protocols in Australia screen for myocarditis for patients who are initiating clozapine therapy and for long term monitoring for cardiomyopathy with echocardiography.
Coordinated care between tertiary providers, general practitioners and primary health care professionals should monitor the physical health of people with psychosis or schizophrenia at least annually and treatment should be offered accordingly.

1 Concord Repatriation General Hospital, Sydney, NSW
2 ANZAC Research Institute, Sydney, NSW
3 Collaborative Centre for Cardiometabolic Health in Psychosis, Sydney Local Health District, Sydney, NSW
4 University of Sydney, Sydney, NSW

Correspondence: leonard.kritharides@sydney.edu.au

Competing interests:

No relevant disclosures.

1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386: 743-800.
2. Galletly C, Castle D, Dark F, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016; 50: 410-472.
3. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009; 113: 1-11.
4. Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 2012; 25: 83-88.
5. Olfson M, Gerhard T, Huang C, et al. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72: 1172-1181.
6. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80: 45-53.
7. Gale CR, Batty GD, Osborn DP, et al. Mental disorders across the adult life course and future coronary heart disease: evidence for general susceptibility. Circulation 2014; 129: 186-193.
8. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115-1121.
9. Ruschena D, Mullen PE, Burgess P, et al. Sudden death in psychiatric patients. Br J Psychiatry 1998; 172: 331-336.
10. Sweeting J, Duflou J, Semsarian C. Postmortem analysis of cardiovascular deaths in schizophrenia: a 10-year review. Schizophr Res 2013; 150: 398-403.
11. Cooper J, Mancuso SG, Borland R, et al. Tobacco smoking among people living with a psychotic illness: the second Australian Survey of Psychosis. Aust N Z J Psychiatry 2012; 46: 851-863.
12. Bergman BC, Perreault L, Hunerdosse D, et al. Novel and reversible mechanisms of smoking-induced insulin resistance in humans. Diabetes 2012; 61: 3156-3166.
13. Wulff K, Dijk DJ, Middleton B, et al. Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 2012; 200: 308-316.
14. Robillard R, Rogers NL, Whitwell BG, Lambert T. Are cardiometabolic and endocrine abnormalities linked to sleep difficulties in schizophrenia? A hypothesis driven review. Clin Psychopharmacol Neurosci 2012; 10: 1-12.
15. Foley DL, Mackinnon A, Morgan VA, et al. Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry 2015; 2: 1092-1098.
16. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006; 113: 791-798.
17. Chen S, Broqueres-You D, Yang G, et al. Male sex may be associated with higher metabolic risk in first-episode schizophrenia patients: A preliminary study. Asian J Psychiatr 2016; 21: 25-30.
18. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol 2007; 27: 374-379.
19. Enez Darcin A, Yalcin Cavus S, Dilbaz N, et al. Metabolic syndrome in drug-naïve and drug-free patients with schizophrenia and in their siblings. Schizophr Res 2015; 166: 201-206.
20. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
21. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989; 1: 495.
22. Andreassen OA, Djurovic S, Thompson WK, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet 2013; 92: 197-209.
23. Dasgupta A, Singh OP, Rout JK, et al. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1202-1207.
24. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302: 1765-1773.
25. Misiak B, Kiejna A, Frydecka D. The history of childhood trauma is associated with lipid disturbances and blood pressure in adult first-episode schizophrenia patients. Gen Hosp Psychiatry 2015; 37: 365-367.
26. Bartoli F, Crocamo C, Caslini M, et al. Schizoaffective disorder and metabolic syndrome: A meta-analytic comparison with schizophrenia and other non-affective psychoses. J Psychiatr Res 2015; 66–67: 127-134.
27. Wysokinski A, Strzelecki D, Kloszewska I. Levels of triglycerides, cholesterol, LDL, HDL and glucose in patients with schizophrenia, unipolar depression and bipolar disorder. Diabetes Metab Syndr 2015; 9: 168-176.
28. Saari K, Koponen H, Laitinen J, et al. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004; 65: 547-550.
29. Ballon J, Stroup T. Polypharmacy for schizophrenia. Curr Opin Psychiatry 2013; 26: 208-213.
30. Vincenzi B, Greene C, Ulloa M, et al. Lithium or valproate adjunctive therapy to second-generation antipsychotics and metabolic variables in patients with schizophrenia or schizoaffective disorder. J Psychiatr Pract 2016; 22: 175-182.
31. Correll CU, Detraux J, De Lepeleire J, de Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015; 14: 119-136.
32. Qiao Y, Zhang L, He S, et al. Plasma metabonomics study of first-episode schizophrenia treated with olanzapine in female patients. Neurosci Lett 2016; 617: 270-276.
33. de Leon J, Susce M, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95-102.
34. Koro CE, Fedder DO, L’Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021-1026.
35. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384: 626-635.
36. Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl 2011; 12: 267-270.
37. De Hert M, Kalnicka D, van Winkel R, et al. Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. Journal Clin Psychiatry 2006; 67: 1889-1896.
38. Reith C, Armitage J. Management of residual risk after statin therapy. Atherosclerosis 2016; 245: 161-170.
39. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008; 102: 1K-34K.
40. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
41. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-1574.
42. Kanzaki T, Uju Y, Sekine K, et al. Increased silent brain infarction accompanied with high prevalence of diabetes and dyslipidemia in psychiatric inpatients. Prim Care Companion CNS Disord 2015; 17.
43. McLean G, Martin JL, Martin DJ, et al. Standard cardiovascular disease risk algorithms underestimate the risk of cardiovascular disease in schizophrenia: evidence from a national primary care database. Schizophr Res 2014; 159: 176-181.
44. Foley DL, Mackinnon A, Morgan VA, et al. Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample. Aust N Z J Psychiatry 2015; 49: 714-723.
45. Osborn DP, Hardoon S, Omar RZ, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry 2015; 72: 143-151.
46. Henderson DC, Vincenzi B, Andrea NV, et al. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015; 2: 452-464.
47. Chow V, Reddel C, Pennings G, et al. Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophr Res 2015; 162: 175-182.
48. Galletly CA, Foley DL, Waterreus A, et al. Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46: 753-761.
49. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction 2010; 105: 1176-1189.
50. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
51. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196: 116-121.
52. Mitchell AJ, Lawrence D. Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis. Br J Psychiatry 2011; 198: 434-441.
53. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-610.
54. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25: 32-41.
55. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45: 458-465.
56. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-1845.
57. Scelsa SN, Simpson DM, McQuistion HL, et al. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology- 1996; 47: 1518-1523.
58. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 2009; 190: 190-192. <MJA full text>
59. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487.
60. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345: 224-225.
61. Reznik I, Volchek L, Mester R, et al. Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol- 2000; 23: 276-280.
62. Chow V, Feijo I, Trieu J, et al. Successful rechallenge of clozapine therapy following previous clozapine-induced myocarditis confirmed on cardiac MRI. J Child Adolesc Psychopharmacol 2014; 24: 99-101.
63. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-327.
64. Laugharne J, Waterreus AJ, Castle DJ, Dragovic M. Screening for the metabolic syndrome in Australia: a national survey of psychiatrists’ attitudes and reported practice in patients prescribed antipsychotic drugs. Australas Psychiatry 2016; 24: 62-66.
65. Baxter AJ, Harris MG, Khatib Y, et al. Reducing excess mortality due to chronic disease in people with severe mental illness: meta-review of health interventions. Br J Psychiatry 2016; 208: 322-329.
66. Barbui C, Girlanda F, Ay E, et al. Implementation of treatment guidelines for specialist mental health care. Cochrane Database Syst Rev 2014; 1: CD009780.
67. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry 2011; 199: 99-105.
68. National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: prevention and management. Clinical guideline. London: NICE; 2014. https://www.nice.org.uk/guidance/cg178 (accessed May 2016).
69. Oakley Browne M, Lambert T, Reavley N, Jorm A. Physical health care of people with enduring psychotic illness. Aust N Z J Psychiatry 2015; 49 Suppl 1: 24.
70. Mitchell AJ, Delaffon V, Vancampfort D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42: 125-147.
71. Casalino LP, Dunham D, Chin MH, et al. Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med 2009; 169: 1123-1129.

Online responses are no longer available. Please refer to our instructions for authors page for more information.

Cardiovascular disease in patients with schizophrenia

Topics

Summary

Author

Comment

Do you have any competing interests to declare? *